The experimental gene therapy Engensis (VM202) was found to be safe and showed early signs of benefit for people with Charcot-Marie-Tooth disease type 1A (CMT1A), according to results from a small Phase 1/2a clinical trial. Treatment reduced disease severity, mainly by easing sensory neuropathy, or nerve damage affecting sensation, and lessened…